Artoss: DAPA Agreement for NanoBone Bone Graft
Elizabeth Hofheinz, M.P.H., M.Ed. • Wed, September 27th, 2017
Artoss, Inc. has announced that the full line of NanoBone Bone Graft products is available through a Defense Acquisition Purchasing Agreement (DAPA) with the Prime Vendor, Owens & Minor. This agreement means that surgeons in any U.S. Department of Defense healthcare facility can purchase NanoBone Bone Graft.
Paul Byerley, managing director of Artoss, the exclusive North American distributors for NanoBone in orthopedic surgery, said in the September 15, 2017 news release, “Nanotechnology is the key technology for the 21st century and NanoBone Bone Graft brings Applied NanoBiology to bone repair. We are proud to provide NanoBone to military surgeons that are providing the highest quality of care to our men and women in uniform.”
As the company wrote in its news release, “NanoBone Bone Graft products have been used in Europe and the U.S. for more than ten years in approaching 400,000 clinical cases across all indications. They have been available in the United States through Artoss, Inc. since 2015.”
James J. Cassidy, Ph.D. is managing director at Artoss. Dr. Cassidy told OTW, “Artoss worked with the Defense Logistics Agency (DLA) and the Medical/Surgical Prime Vendor, Owens & Minor, to register the full NanoBone Bone Graft product line. The Distribution and Pricing Agreement (DAPA) allows the DLA Troop Support Medical Supply Chain to distribute NanoBone to Department of Defense Healthcare facilities.”
“Surgeons operating in Department of Defense healthcare facilities now have an easily applied, standalone bone graft incorporating nanotechnology to use in caring for our men and women in uniform.”